[肝细胞癌的靶向治疗]
[Targeted therapies in hepatocellular carcinoma].
作者信息
Bouattour Mohamed, Marijon Hélène, Dreyer Chantal, Faivre Sandrine, Raymond Eric
机构信息
Service inter-hospitalier de cancérologie Bichat-Beaujon, hôpital Beaujon, 92110 Clichy, France.
出版信息
Presse Med. 2010 Jul-Aug;39(7-8):753-64. doi: 10.1016/j.lpm.2009.11.016. Epub 2010 Apr 7.
Hepatocellular carcinoma (HCC) stands as a major health problem worldwide. The management of advanced HCC, limited for a longtime by the disappointing results of conventional cytotoxic chemotherapies, has recently changed with the publication of the results of the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial, which demonstrated an overall survival benefit over placebo in patients with advanced HCC. This study was further confirmed by the Asian-Pacific trial using sorafenib in Eastern patients. Those trials demonstrated that therapeutic benefits may derive from improving our knowledge of deregulated signaling pathways involved in HCC carcinogenesis. This review summarizes the results of clinical trials in which targeted therapies are currently evaluated aiming to enlarge the therapeutic armamentarium for HCC in a near future.
肝细胞癌（HCC）是全球主要的健康问题。长期以来，晚期HCC的治疗因传统细胞毒性化疗效果不佳而受限，随着索拉非尼肝细胞癌评估随机试验（SHARP）结果的公布，情况最近有所改变，该试验表明晚期HCC患者使用索拉非尼比使用安慰剂有总生存期获益。亚太地区在东方患者中使用索拉非尼的试验进一步证实了这项研究。这些试验表明，治疗获益可能源于我们对HCC致癌过程中失调信号通路认识的提高。本综述总结了目前正在评估靶向治疗的临床试验结果，旨在在不久的将来扩大HCC的治疗手段。
Zotero 插件